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Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) may experience an acute worsening of
respiratory symptoms that results in additional therapy; this event is defined as a COPD exacerbation (AECOPD).
Hospitalization for AECOPD is accompanied by a rapid decline in health status with a high risk of mortality or other
negative outcomes such as need for endotracheal intubation or intensive care unit (ICU) admission. Treatments for
AECOPD aim to minimize the negative impact of the current exacerbation and to prevent subsequent events, such
as relapse or readmission to hospital.
Main body: In this narrative review, we update the scientific evidence about the in-hospital pharmacological and
non-pharmacological treatments used in the management of a severe AECOPD. We review inhaled bronchodilators,
steroids, and antibiotics for the pharmacological approach, and oxygen, high flow nasal cannulae (HFNC) oxygen
therapy, non-invasive mechanical ventilation (NIMV) and pulmonary rehabilitation (PR) as non-pharmacological
treatments. We also review some studies of non-conventional drugs that have been proposed for severe AECOPD.
Conclusion: Several treatments exist for severe AECOPD patients requiring hospitalization. Some treatments such as
steroids and NIMV (in patients admitted with a hypercapnic acute respiratory failure and respiratory acidosis) are
supported by strong evidence of their efficacy. HFNC oxygen therapy needs further prospective studies. Although
antibiotics are preferred in ICU patients, there is a lack of evidence regarding the preferred drugs and optimal
duration of treatment for non-ICU patients. Early rehabilitation, if associated with standard treatment of patients, is
recommended due to its feasibility and safety. There are currently few promising new drugs or new applications of
existing drugs.
Keywords: COPD, Acute exacerbation, Hospitalization, Steroids, Antibiotics, Oxygen, High flow nasal cannulae
oxygen therapy, Non-invasive mechanical ventilation, Pulmonary rehabilitation
Background
In the natural history of disease, patients with chronic
obstructive pulmonary disease (COPD) may experience
an acute worsening of the clinical condition that is de-
scribed as a COPD exacerbation (AECOPD) [1]. AECOPD
may be triggered by respiratory viral and bacterial infec-
tion [2]; pollution or ambient temperature may also initi-
ate or amplify AECOPD [2]. Characterized by increased
systemic inflammatory activity [3], AECOPD has a nega-
tive impact on patients’ health status and outcomes [4, 5].
What is an AECOPD? Definitions
The absence of homogeneity in the definition of an
AECOPD has opened controversial opinions in the last
few years. The possibility to define in the same ways the
AECOPD could have implications on decision-making,
changing therapeutic interventions in clinical trials [6, 7].
In the ‘80s, although the Anthonisen criteria [8] were
based on patients’ symptoms reporting an AECOPD (in-
crease of dyspnea, sputum purulence and sputum vol-
ume), the presence of a change in sputum characteristics,
with increased cough and wheeze, could identify an
AECOPD needing a specific antibiotic approach. From
Anthonisen criteria, several definitions have been pro-
posed, but in general they are based on changes in patient
symptoms (dyspnea, cough, sputum) or on healthcare
resources requirement (drugs, hospitalisation), or on
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combinations of both [6, 7]. In this context, the three re-
cent documents related to experts consensus about man-
agement of AECOPD (the Global Initiative for Chronic
Obstructive Lung Disease-GOLD document [1], the
National Institute of Health and Clinical Excellence-NICE
guidelines [9] and the European Respiratory Society/
American Thoracic Society ERS/ATS guidelines [10]) de-
scribe definitions of AECOPD based on onset of symp-
toms and need of additional therapy (Table 1). Although
these definitions may be usefull in the clinical practice,
this approach may be too pragmatic, oversimplifing the
pathogenic pathways implicated [7]. Very recently, in a
holistic approach, more precise definitions of AECOPD
have been considered to include not only clinical variables
[7, 11, 12]; this approach may be more accurate for the
differential diagnosis with other respiratory diseases.
When AECOPD is severe and needs a
hospitalization
Although the severity of AECOPD may be classified ac-
cording to the use of medications [1], in severe AECOPD
that requires hospitalization the early recognition of acute
respiratory failure (ARF), either non-life- or life-threatening
[1, 13] (Table 2), may be crucial for correct selection of
treatment. Table 3 reports potential indicators for identify-
ing when severe AECOPD patients require hospitalization
in a medical ward or in a respiratory or medical intensive
care unit (ICU) [1].
Why a severe AECOPD is important?
Hospitalization for AECOPD worsens the course of
COPD disease and involves a rapid decline in health sta-
tus associated with high mortality [5, 14, 15]. Although
male gender has been identified as a risk factor for
higher morbidity and mortality in AECOPD [14], recent
data indicate that female COPD patients may have a
higher number of hospitalizations with a prolonged length
of stay [16]. In any case, severe AECOPD increases the
possibility of subsequent COPD-related hospitalizations
[5], with potential causal associations among past and
future severe exacerbations [17]. This could be related also
to a distinct phenotype of COPD, the frequent exacerbator
[18], worsening the clinical outcomes [19]. In this context,
a history of at least two prior incidents of severe AECOPD
is associated with a new severe event (adjusted odds ratio
[OR] 6.73; 95% confidence interval [CI], 3.53 to 12.83) and
an increased risk of death (adjusted OR 7.63; 95% CI 3.41
to 17.05) [20]. Variables related to age, low body mass
index, cardiac failure, diabetes mellitus, ischemic heart
disease, malignancy, forced expiratory volume in the 1st
second (FEV1), long-term oxygen therapy, and the partial
arterial oxygen pressure (PaO2) on admission of severe
AECOPD were significantly associated with long-term
mortality during a 2-year follow up period [21]. The pres-
ence of coexisting asthma has also been proved to be asso-
ciated with frequent severe AECOPD [22]. In general for a
severe hospitalized AECOPD, the weighted average of the
in-hospital mortality, and of the mortality at 1 year and
5 years, is 6.7% (95% CI 5.7 to 7.7), 33% (95% CI 25 to 40)
and 51% (95% CI 38 to 63), respectively [23]. Recent evi-
dence about worse outcomes in hospitalized AECOPD
shows links with the presence of hyponatremia [24], hypo-
albuminemia [25], ischemic heart disease [26], and acute
kidney injury [27]. Recently, an English study reported
that patients having a pulmonary arterial enlargement, de-
fined by a pulmonary artery to aorta (PA/A) ratio > 1 at
chest CT scan, associated with an increased level of tropo-
nin (> 0.01 ng/mL), had an increased probability of having
ARF, ICU admission or in-hospital mortality in compari-
son to patients without both these factors [28].
Why a treatment in a severe AECOPD is
important?
Treatments for AECOPD aim to minimize the negative
impact of the current exacerbation and to prevent subse-
quent events [1], such as the relapse of AECOPD [29]
and, in cases of hospitalization, reduce early readmis-
sions to hospital [30] occurring within ≤30 days of dis-
charge. Although there are known predictors of early
readmission [31–33], re-hospitalization for a new severe
event is required in 18% of AECOPD patients admitted
[34] and was associated with a subsequent progressive
increase in the risk of death in a long-term follow up
[34]; for this reason, early readmission should be consid-
ered in these patients as a marker of more severe disease
with a worse prognosis [35]. Although the initial treat-
ment may be a useful predictor of subsequent clinical
outcomes [36], treatment failure, which occurs in 14%
[37] to 18% [38] of treated patients, may be predicted by
a measure of daily health status (by the Clinical COPD
Table 1 Definitions of AECOPD according to the GOLD document, NICE guidelines and ERS/ATS guidelines
GOLD document Acute worsening of respiratory symptoms that results in additional therapy.
NICE guidelines A worsening of the patient’s symptoms from their usual stable state which is beyond
normal day-to-day variations, and is acute in onset. Commonly reported symptoms are
worsening breathlessness, cough, increased sputum production and change in sputum
colour. The change in these symptoms often necessitates a change in medication.
ERS/ATS guidelines Episodes of increasing respiratory symptoms, particularly dyspnea, cough and sputum
production, and increased sputum purulence
Reported from references [1, 9, 10]
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Questionnaire-CCQ) [38]; moreover, an increased in-
flammatory level at admission (C-reactive protein [CRP]
+ 1 mg/dL OR 1.07; 95% CI 1.01 to 1.13) and the use of
penicillins or cephalosporins (OR 5.63; 95% CI 1.26 to
25.07) were independently associated with an increased
risk of treatment failure, whereas cough at admission
(OR 0.20; 95% CI 0.05 to 0.75) was associated with a
lower risk [37].
In this narrative review, based on a search on Medline
completed in the month of May 2018, we update the sci-
entific evidence about the in-hospital pharmacological
and non-pharmacological treatments used in the man-
agement of a severe AECOPD. For the pharmacological
approach we have divided the evidence according to the
class of drugs (inhaled bronchodilators, steroids, and
antibiotics). Non-pharmacological treatments include
the use of oxygen, high flow nasal cannulae (HFNC)
oxygen therapy, and non-invasive mechanical ventilation
(NIMV) and pulmonary rehabilitation (PR). Finally, we
review some studies concerning non-conventional drugs
that have also been proposed for severe AECOPD.
Bronchodilators
Although recommended with or without short-acting
anticholinergics as the initial bronchodilators to treat an
AECOPD, short-acting β2 agonists (SABA) have no
high-quality evidence from randomized-control trials
[1]. The use of these medications is in line with recent
treatment patterns of hospitalized patients [39] in which
only 5% of patients did not receive a SABA, while 72%
received a single-product SABA and 46% received a
combination with SABA plus a short-acting anticholin-
ergic [39].
Table 2 Severity of hospitalized AECOPD patients






Supplemental oxygen given via
Venturi mask able to improve
hypoxemia (FiO2%)
PCO2 pH
No respiratory failure 20–30 No No 28–35 Normal Normal
Acute respiratory failure
(non-life-threatening)





> 30 Yes Yes > 40 or not improved Increased
(> 60 mmHg)
≤ 7.25
Modified from references [1, 13]
Abbreviations: FiO2 indicates fraction of inspired oxygen, PaCO2, partial arterial carbon dioxide pressure
Table 3 Potential indicators for do-not-hospitalize AECOPD patients or hospitalization in a general ward or in a respiratory or
medical intensive care units (ICU)
Variables Do-not-hospitalize General ward Respiratory or medical ICU
Insufficient home support X
Good response to initial medical management X
Failed response to initial medical management X
Fewer symptoms (dyspnea on effort, RR < 30
breaths/min, SatO2 > 90%, no confusion, no drowsiness)
X
Severe symptoms (resting dyspnea, RR ≥ 30 breaths/min,
SatO2≤ 90%, confusion, drowsiness)
X
Very severe symptoms (dyspnea) that respond inadequately
to initial emergency therapy
X
Presence of serious comorbidities (e.g. heart failure, newly
occurring arrhythmias, etc.)
X
Onset of new physical signs (e.g. cyanosis, peripheral edema) X
Acute respiratory failure (without use of accessory respiratory
muscles and change in mental status)
X
Acute respiratory failure (with use of accessory respiratory
muscles and change in mental status)
X
Persistent or worsening hypoxemia (PO2 < 40 mmHg)
and/or severe respiratory acidosis (pH < 7.25)
X
Need for IMV X
Hemodynamic instability (need for vasopressors) X
Modified from report [1]. The cross mark identifies the correct setting
Abbreviations: RR indicates respiratory rate, SatO2 oxygen saturation, PaO2 partial arterial oxygen pressure, IMV invasive mechanical ventilation
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A Canadian meta-analysis performed in COPD pa-
tients with an acute airflow obstruction found no dif-
ference in the effect of bronchodilator delivery by a
metered-dose inhaler (MDI) or wet nebulizer based
on objective measurements [40]. Similarly, a recent
Cochrane review comparing the effects of nebulizers
versus pressurized MDI (pMDI) plus spacer or dry
powder inhalers (DPI) [41] found no significant differ-
ence in the change in FEV1 at 1 h after dosing be-
tween nebulizers versus pMDI plus spacer although
there was a trend for greater improvement in FEV1
when treating with nebulizers [41]. No data of suffi-
cient quality have been published comparing nebu-
lizers versus DPIs [41]. In conclusion, the limitations
of the difficult-to-pool and low-quality data did not
permit the authors to provide evidence to favor one
mode of delivery over another [41].
In general, spacer devices are recommended for bron-
chodilator delivery with a pMDI [1]. A study evaluating
the necessary inspiratory flow using different DPIs in
patients admitted to hospital during an AECOPD dem-
onstrated the ability of patients to use these inhalers
[42]. At admission, the median (interquartile range) of
inspiratory flow (L/minutes) using the appropriate sim-
ulators of the resistance and the percentage of patients
(%) achieving the minimum necessary inspiratory flow
of 30 L/min required for each DPI device were 40 L/m
(30–50) (91%), 50 L/m (40–60) (95%), 60 L/m
(50–87.5) (100%), and 30 L/m (20–40) (82%) for
Turbuhaler®, Diskus®, Aerolizer®, and Handihaler®, re-
spectively [42]. This might open up the possibility of
using long-acting β2 agonists (LABA) for the treatment
of AECOPD [43]. A proof of concept [44] performed in
AECOPD patients having a mild-to-moderate worsen-
ing of dyspnea demonstrated that an early treatment
with doubling dose of a combination of a LABA
(Salmeterol) plus an inhaled corticosteroid (ICS, Fluti-
casone Propionate) for 10 days has a potential effect
avoiding the requirement of prednisone within 30 days
of the onset. In a single-center, open-label, randomized,
crossover, and single-blind trial on 12 hospitalized
AECOPD patients, a recent study exploring the acute
effect of indacaterol found a significant mean increase
in FEV1 and forced vital capacity (FVC), with the
highest increase at the dose of 300 mg; however,
transient episodes of oxygen desaturation were observed
in some patients with relatively well-preserved PaO2
(− 5.9 mmHg [95% CI -1.4 to − 10.4] and − 6.2 mmHg
[95% CI -2.7 to − 9.8] in the mean peak in PaO2 over 6 h
in the group treated with indacaterol 150 mg and
indacaterol 300 mg, respectively) [45]. Similar increases
were observed when indacaterol was administered over
5 days in the emergency department in comparison to
salbutamol [46].
Main take home messages
The large use of SABA and short-acting anticholinergics
during an AECOPD is a common therapeutic practice,
although to date there are not solid evidences. There are
also limitated data about the better bronchodilator deliv-
ery. The use of LABA during AECOPD, although limi-
tated, could have large employ in the manteinance
therapy after discharge.
Unmet needs or future clinical research
There are not quality data about the use of long-acting
muscarinic antagonists (LAMA) during a severe AECOPD.
In the era of dual bronchodilation in the treatment for
COPD [47] this represents a strong unmet needs that
should be investigated.
Steroids
There is strong evidence for the use of systemic steroids
in severe AECOPD [10]. This has been reported in the
recent European Respiratory Society/American Thoracic
Society consensus guideline providing clinical recom-
mendations for the treatment of AECOPD [10].
Several studies have demonstrated an improvement of
several outcomes in AECOPD patients using systemic
steroids, including length of hospital stay [48, 49],
in-hospital oxygenation [48, 49], FEV1 [48–50], dyspnea
[50], risk of relapse [50], and rate of treatment failure
[49, 51]. Prednisone/prednisolone is the preferred intra-
venous or oral steroid [48, 50, 52–54]. The oral adminis-
tration of prednisolone is as effective as intravenous
administration [53]. A short duration of treatment is
preferred to a long duration [52, 55]. Several studies
have been performed on hospitalized AECOPD but not
on ICU patients [48–50], while some have been per-
formed in critically ill patients [51, 56].
In 1999, two studies [48, 49] performed in patients
without ARF and placebo-control demonstrated the effi-
cacy of oral prednisolone (30 mg for 14 days) [48] and
intravenous methylprednisolone (500 mg for 3 days
followed by oral prednisone 60 mg for 4 days with a sca-
lar dose until 8 or 2 weeks, according to the study
group) [49] at improving FEV1 and reducing hospital
stay. For the first time in trials, the latter study [49] re-
ported treatment failure as a primary outcome, defined
by the assessment of in-hospital deaths due to any cause,
the need for NIMV or ICU admission, hospital readmis-
sion, and the need for intensification of therapy. The
authors demonstrated a lower rate of combined failure
variables at 30 days (23% versus 33%, p = 0.04) and at
90 days (37% versus 48%, p = 0.04) in patients using
steroids in comparison to placebo [49]. Finally, in a
three-arm design (patients receiving 8 or 2 weeks of ste-
roids and patients receiving placebo) it was demon-
strated that the long steroid regimen of 8 weeks did not
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increase the clinical benefits of a short regimen of
2 weeks [49].
To study the outcomes of the risk of relapse after a
severe AECOPD, Aaron and colleagues [50] enrolled
AECOPD patients who were being discharged from the
emergency department and treated with 40 mg of oral
prednisone for 10 days. The authors found a lower rate
of relapse at 30 days (27% versus 43%, p = 0.05) and a
longer time to relapse (23 days versus 7 days, hazards ra-
tio 0.56 [95% CI 0.32 to 0.99], p = 0.04) in patients with
steroids versus placebo [50]. Furthermore, patients
treated with prednisone showed improvements in their
FEV1 (from day 1 to day 10) and dyspnea scores [50].
Studies performed specifically in mechanically venti-
lated AECOPD patients or those admitted to the ICU
include the Spanish double-blind, placebo-controlled
trial of Alía and colleagues [51], which was performed
on 83 acidotic AECOPD patients who received intraven-
ous methylprednisolone (from a dose of 2 mg/kg/day for
3 days to 0.5 mg/kg/day from days 7 through 10). Pa-
tients in the steroid group showed a reduction in the
duration of mechanical ventilation in comparison to pla-
cebo (median [interquartile range], 3 days [2–6] versus
4 days [3–7], p = 0.04, respectively) [51]; however, when
comparing patients with conventional ventilation (46 pa-
tients) and NIMV (37 patients) the use of steroids did
not appear to reduce the duration of ventilation in com-
parison to the placebo. Interestingly, the rate of NIMV
was lower in the steroid group (0%) in comparison to
the placebo (37%). Another prospective, open-label,
randomized, placebo-controlled trial on the use of oral
prednisone (1 mg/kg/day for up to 10 days) performed
on 217 acidotic AECOPD patients requiring initial con-
ventional mechanical ventilation (n = 53) or NIMV (n =
164), found contrasting findings [56]. There was no dif-
ference in primary outcomes (ICU mortality, evaluated
in all ventilated and in conventional and NIMV) or sec-
ondary outcomes (failure of NIMV, duration of mechan-
ical ventilation, ICU length of stay) [56]. The different
doses of steroid used in the studies [51, 56] and the
severity of AECOPD (more severe respiratory acidosis
and hypercapnia in the latter [56]) may explain the dif-
ferent results.
With regards to the route of steroid administration
(parenteral versus oral), a study has demonstrated that
oral administration with prednisolone (60 mg for 5 days)
was no less effective than intravenous therapy [53], with
no difference in treatment failure in the early phase
(within 2 weeks) or at 90 days. The length of hospital stay,
moreover, was similar among the oral administration
(11.2 days) and the intravenous therapy group (11.9 days)
[53]. A recent study [57] comparing AECOPD patients re-
ceiving a fixed, low dose of oral steroids (methylpredniso-
lone 32 mg/day for 7 days) with patients receiving higher
doses of intravenous steroids (methylprednisolone at
1 mg/kg/day for 4 days and 0.5 mg/kg/day for 3 days)
demonstrated similar results between study groups in
terms of lung function, symptoms and oxygenation [57].
In line with these findings about the optimal dose and
route of steroid administration, a pharmacoepidemiologi-
cal cohort study conducted in more than 400 US hospitals
involving almost 80,000 AECOPD patients [58] demon-
strated that the risk of treatment failure (initiation of
mechanical ventilation, in-hospital mortality, or readmis-
sion for AECOPD within 30 days of discharge) among
patients treated with low doses of steroids administered
orally was not worse than for those treated with higher
doses administered intravenously [58]. In the context of
the optimal dose of steroids in AECOPD patients treated
in the ICU, another recent pharmacoepidemiological co-
hort study [59] performed in 473 hospitals on more than
17,000 patients examined the effectiveness and safety of a
lower dose (methylprednisolone ≤240 mg/day) versus a
higher dose (methylprednisolone > 240 mg/day) of ste-
roids [59]. The authors found that patients using lower
versus higher doses of steroids had similar hospital mor-
tality (OR 0.85; 95% CI 0.71 to 1.01; p = 0.06), defined as a
primary outcome. However, a lower dose of steroids was
associated with a reduced length of hospital and ICU stay,
hospital costs, length of invasive ventilation, need for insu-
lin therapy, and fungal infection [59].
Based on the concept that the use of systemic corti-
costeroids for a longer time is associated with adverse
effects such as osteoporosis, hyperglycemia and muscle
weakness, the noteworthy trial of Leuppi and colleagues
[52] (REDUCE: Reduction in the Use of Corticosteroids
in Exacerbated COPD), published in 2013, defined the
optimal dose (prednisone 40 mg daily) and duration of
steroid treatment (5 days) in hospitalized AECOPD.
The short-term treatment of 5 days, in fact, was
non-inferior to conventional treatment (14 days). The
percentage of patients having a new exacerbation (me-
dian 180 days of follow up) was lower in the short-term
treatment in comparison to conventional treatment
(36% versus 37%, p = 0.006 for the intention-to-treat
[ITT] analysis, and 37% versus 38%, p = 0.005 in the
per-protocol [PP] analysis, respectively). Similarly, the
duration of hospital stay was lower (median 8 days
[IQR 5–11] versus 9 days [IQR 6–14]; p = 0.04, respect-
ively) and the cumulative prednisone dose (difference
in mean − 414 mg.; p < 0.001) was lower in the
short-term group in comparison to the conventional
group [52]. A Cochrane review, updated in 2018 [55]
suggests that in a severe AECOPD the likelihood of
having a worse outcome is lower in patients using an
oral steroid for 5 days than with a longer course (10 to
14 days) [55]. This review [55], however, excluded stud-
ies with patients requiring assisted ventilation. In this
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context, a previous study performed on AECOPD re-
quiring hospitalization but with ARF and comparing
the same dose of methylprednisolone (2 mg/kg/day)
but with different duration (3 or 10 days) [60] did not
confirm that a short treatment is better for these pa-
tients. In fact, although both study groups (3 and
10 days) experienced improvements in oxygenation and
FEV1, and the re-exacerbation rate at 6 months was
similar, the improvements were more marked over the
course of 10 days of steroids, as were those in FVC and
dyspnea on exertion [60].
Although domiciliary inhaled corticosteroids do not
influence the early inflammatory response and the
clinical presentation of hospitalized AECOPD [61], the
use of these medications during an AECOPD may be a
valid alternative to systemic steroids for hospitalized
patients as well; this approach might reduce the risk
of side effects. A multicenter, double-blind, random-
ized, placebo-controlled trial performed on 199 not
acidotic and not hypercapnic AECOPD patients com-
pared nebulized budesonide (2 mg four times/day) and
oral steroids (prednisolone 60 mg/day) [62]. In
comparison to placebo, both treatments (budesonide
and prednisolone) demonstrated an improvement in
post-bronchodilator FEV1 and the difference between
the two groups was not significant [62]. Another trial
[63] performed on AECOPD patients without a severe
airflow obstruction and without a ARF (hypercapnic
patients with a partial arterial carbon dioxide
pressure-PaCO2 > 70 mmHg were excluded a priori),
was aimed to evaluate the clinical efficacy of compari-
son between nebulized budesonide (2 mg three times/
day) versus intravenous methylprednisolone (40 mg/
day). Both groups showed similar improvements in
symptoms, pulmonary function and arterial blood gas
analysis, although the incidence of adverse events was
lower in the budesonide group [63].
Main take home messages
The use of steroids during a severe AECOPD appears
justified from solid evidences. This is confirmed by im-
provements on several in-hospital (symptoms, length of
hospital stay, treatment failure) and post-discharge (risk
of relapse) outcomes. The oral administration should be
preferred due to the similar efficacy of intravenous and
for the limitation of systemic effects.
Unmet needs or future clinical research
In COPD patients molecular and immunological mecha-
nisms of steroid resistance are documented [64]. To iden-
tify a cluster of steroid-responder patients could highlight
a different therapeutic approach in the management of se-
vere AECOPD.
Antibiotics
Data coming from sputum cultures suggest that bacterial
infection is a more prevalent cause of AECOPD [2, 65, 66],
with a correlation between sputum color and the presence
of potentially pathogenic bacteria [67, 68]. In general, a
sputum color of green or yellow was most likely to yield
potentially pathogenic microorganisms (59% and 45%, re-
spectively), in comparison to clear (18%) and rust-coloured
sputum (39%) [67]; sputum color predicts a positive cul-
ture [67]. In severe AECOPD patients requiring mechan-
ical ventilation, potentially pathogenic microorganisms
(PPMs) and/or a positive serology were present in 72% of
patients [69]. A bronchial microbiological pattern corre-
sponding to community-acquired pathogens (Streptococcus
pneumoniae, Haemophilus influenzae, and Moraxella
catarrhalis) was present in 56% of positive samples, while a
high percentage of positive samples (44%) contained
gram-negative enteric bacilli (GNEB), Pseudomonas, and
Stenotrophomonas spp. [69]. Interestingly, the presence of
pathogens was clinically unpredictable [69]. Being a
non-current smoker, ≥ 2 AECOPD or ≥ 1 admission for
AECOPD in the previous year and a CRP < 5 mg/dL were
proved to be independent factors predicting the presence
of microorganisms resistant to conventional treatment
(MRCT) (40% of isolates in hospitalized AECOPD pa-
tients) [70]; in this context, although patients with MRCT
had longer hospital stays, the mortality rate at 30 days, 1
year and 3 years was comparable to that of patients with
microorganisms sensitive to conventional antimicrobial
treatment (MSCT) [70]. In any case, the use of antibiotics
is recommended in AECOPD with sputum purulence and
especially for very severe patients [67–70].
Recently, with the aim of differentiating among chronic
colonization and acute infection in AECOPD patients,
levels of procalcitonin have been considered as a marker
for the use of antibiotics [71, 72]. An updated Cochrane
meta-analysis [73] showed that in acute respiratory tract
infections the use of procalcitonin is useful to initiate or
discontinue antibiotics; this results in lower risks of mor-
tality, lower antibiotic consumption, and lower risk for
antibiotic-related side effects [73]. In severe AECOPD pa-
tients with low serum procalcitonin values (< 0.1 ng/ml),
treatment with antibiotics has no benefits in comparison
to placebo [74].
The use of antibiotics in AECOPD without signs of in-
fections remains controversial [1]. The recommendation
regarding length of antibiotic therapy (5 to 7 days) in
AECOPD [1, 75] originates from the use of levofloxacin
500 mg, which has achieved clinical and bacteriological
success regardless of the therapeutic course (5 or 7 days)
[75]. However, this evidence was obtained in patients be-
ing managed in the community as either general practice
patients or outpatients [75] and not in hospitalized se-
vere AECOPD patients. A Cochrane review [76] showed
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that in AECOPD patients who need hospital admission
for severe exacerbations, antibiotics reduce treatment
failures (risk ratio 0.77, 95% CI 0.65 to 0.91, quality of
evidence GRADE [Grading of Recommendations, As-
sessment, Development and Evaluation]: high) but not
the length of hospital stay or mortality (low grade of evi-
dence) [76]. The role of antibiotics is clearer in patients
admitted to the ICU [76], even if documented in only
one study [77]. Antibiotics reduce treatment failures up
to 4 weeks (risk ratio 0.19, 95% CI 0.08 to 0.45, quality
of evidence GRADE: high), all-cause mortality (odds ra-
tio 0.21, 95% CI 0.06 to 0.72, quality of evidence
GRADE: high), and length of hospital stay (mean differ-
ence − 9.60 days; 95% CI -12.84 to − 6.36 days) [76]. The
authors concluded that the benefits of antibiotics in the
ICU are evident [76], while in inpatients the evidence is
inconsistent and stems from old studies [78–80].
With regards to the choice of antibiotic, a randomized,
placebo-controlled trial in 2010 evaluated the effects of
doxycycline (200 mg) in addition to systemic corticoste-
roids [81]. On day 30 treatment success (the primary
outcome defined as the cure or improvement of signs
and/or symptoms of AECOPD, without sign or symp-
toms of infection) was not significant in intention-
to-treat analysis (OR 1.3; 95% CI 0.8 to 2.0; p = 0.32) or
per-protocol [81]. The clinical success at 10 days (sec-
ondary outcome) favored doxycycline (OR 1.9; 95% CI
1.1 to 3.2; p = 0.03) only in ITT, but not in PP. Further-
more, at 10 days doxycycline was superior to placebo in
term of change in bacteriological response, serum CRP
and symptom scores, in particular cough and sputum
purulence [81].
A cornerstone study about the use of antibiotics in severe
AECOPD but requiring mechanical ventilation was the
prospective, randomized, double-blind, placebo-controlled
trial of Nouira and colleagues [77], who evaluated the
effects of a fluoroquinolone, ofloxacin (400 mg for
10 days). In comparison to the placebo (n = 46), pa-
tients using ofloxacin (n = 47) had a reduction in pri-
mary outcomes, in particular percentage of deaths in
the ICU (4% versus 17%, p = 0.05), deaths in hospital
(4% versus 22%, p = 0.01), need for additional course of
antibiotics (6% versus 35%, p = 0.0006), and combined
events (11% versus 57%, p < 0.0001) [77]. Similarly, in
terms of secondary outcomes ofloxacin was superior to
placebo in number of days of mechanical ventilation
(mean 6.4 days ±3.1 versus 10.6 days ±5.1, p = 0.04),
duration of ICU stay (mean 9.4 days ±5.2 versus
14.5 days ±6.0, p = 0.02), and duration of hospital stay
(mean 14.9 days ±7.4 versus 24.5 days ±8.5, p = 0.01)
[77]. The same researchers in the same series of pa-
tients (n = 170) evaluated the combination of trimetho-
prim and sulfamethoxazole (160/800 mg twice daily for
10 days) versus ciprofloxacin (750 mg twice daily for
10 days) in a randomized, double-blind trial [82]. In
this case, the number of deaths in hospital or the ICU,
the need for additional antibiotics, and the combined
events (considered primary outcomes) were similar be-
tween study groups, including the duration in days of
mechanical ventilation, the duration of hospital or ICU
stay, and the exacerbation-free interval (secondary out-
comes) [82]. The authors concluded that the efficacy of
trimethoprim-sulfamethoxazole was similar to that of
ciprofloxacin [82].
Main take home messages
In AECOPD with history of purulent sputum an anti-
biotic is suggested, although the role of this treatment in
hospitalized AECOPD appears controversial and not
fully clear. In patients admitted in ICU it seems have the
major benefit. The levels of procalcitonin could better
identify patients needing an antibiotic therapy.
Unmet needs or future clinical research
Although GOLD guidelines recommend an antibiotic ther-
apy for 5 to 7 days [1], there is not a strong evidence about
the choice of antibiotic and the duration of treatment.
Oxygen therapy, high flow nasal cannulae (HFNC)
oxygen therapy, and non-invasive mechanical
ventilation (NIMV)
The routine use of titrated oxygen treatment is recom-
mended in hospitalized AECOPD, due to the lower risk
of death and lower likelihood of respiratory acidosis or
hypercapnia than in patients who received high flow
oxygen [83]. Blood gases should be monitored to ensure
a good level of oxygenation without carbon dioxide re-
tention and/or worsening acidosis; the PaO2 should be
maintained at 7.3–10 kPa (SaO2 85–92%) to avoid the
dangers of hypoxia and acidosis [84]. A recently devel-
oped device (FreeO2) automatically adjusts the oxygen
flow rates based on patients’ needs, in order to limit
hyperoxia and hypoxemia in hospitalized AECOPD pa-
tients [85]. In comparison to manual oxygen titration
this device improved the percentage of time within the
target SaO2 (significantly higher with FreeO2) and the
time with severe desaturation and hyperoxia (reduced
with FreeO2); furthermore, the length of hospital stay
was lower in patients using FreeO2 [85].
HFNC oxygen therapy is a recent and easy therapeutic
methodical, able to deliver high fraction of inspired
oxygen (FiO2), generating a low level of positive pressure
and providing a washout of nasopharyngeal dead space
[86–89]. The effects of HFNC increase the end-expiratory
lung volume, improve the oxygenation and the breathing
pattern, reduce the work of breathing [86–89]. It is con-
sidered an alternative for patients with severe hypoxemic
ARF [86], although in comparison to conventional oxygen
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therapy and NIMV, a recent systematic review with a
meta-analysis did not show for the HFNC a significant re-
duction of intubation rate and mortality [90]. Similary, a
Cochrane review [91], due to very limited data, is unable
to demonstrate whether HFNC provides an efficacy re-
spiratory support for adult ICU patients. In addition, some
risks of bias among included studies, differences in patient
groups, and high levels of statistical heterogeneity for
some outcomes, lead to uncertainty results [91].
The role of HFNC in stable hypercapnic patients has
been recently demonstrated as safe [92, 93]. HFNC leads
to a flow-dependent reduction in hypercapnia level; this
is most likely achieved by a washout of the respiratory
tract and a functional reduction in dead space [93].
In 24 AECOPD hospitalized patients, a single-centre
randomized-controlled cross-over trial has evaluated the
short-term effects of HFNC on PaCO2 level [94]. Both
interventions (HFNC at 35 l/min and standard oxygen
delivered via nasal prongs) were administred for 30 min,
with oxygen titrated to maintain the patient’s baseline
saturation and with 15 min of washout between inter-
ventions. The difference in transcutaneous carbon diox-
ide tension (PtCO2) at 30 min (primary outcome) was
lower for HFNC compared with standard oxygen (−
1.4 mmHg; 95% CI − 2.2 to − 0.6; p = 0.001). At 30 min,
however, there was no difference between groups in
SaO2 and respiratory rate [94].
In 88 severe AECOPD with moderate hypercapnic
ARF the clinical effectiveness of HFNC has been evalu-
ated in a very recent prospective observational trial in
comparison to NIMV [95] and has failed to demonstrate
any significative effect. The intubation rate and the
30-day mortality were similar between groups, such as
pH, PaO2 and PaCO2 after 6 and 24 h [95]. However,
this study reports methodological, inherent bias and tec-
nical (setting of NIMV) limits that probably can be ex-
plained for different levels of treatment [96].
In COPD patients, the increase in PaCO2 level with re-
spiratory acidosis is associated with a worse outcome
[84, 97, 98], including the risk of ICU admission [84] or
death [84, 97, 98]. Several randomized trials have dem-
onstrated the efficacy of NIMV (using bilevel positive
airway pressure) in AECOPD in comparison to standard
care [99–103]; for this reason data from the Healthcare
Cost and Utilization Project’s Nationwide Inpatient Sam-
ple confirm that the use of this treatment has increased
significantly over time among patients hospitalized for
AECOPD, whereas the need for intubation and in-hospital
mortality has declined [104]. The official ERS/ATS clinical
practice guidelines about noninvasive ventilation for acute
respiratory failure [105], providing evidence-based recom-
mendations, report that in AECOPD patients the use of
NIMV in patients with ARF leading to acute or acute-
on-chronic respiratory acidosis (pH ⩽7.35) is strongly
recommended (GRADE: high level of evidence), while a
conditional recommendation with low certainty of evi-
dence is reported for the prevention of acute respiratory
acidosis (PaCO2 normal or elevated but pH normal) [105].
In the context of respiratory acidosis, NIMV is important
to avoid endotracheal intubation and invasive mechanical
ventilation in patients with mild to moderate acidosis and
respiratory distress, with the aim of preventing deterior-
ation to a point when invasive ventilation would be con-
sidered [105]. The authors of the ERS/ATS guidelines
[105] suggest considering NIMV in AECOPD patients
who develop acute respiratory acidosis during hospital ad-
mission, in particular when the pH is ⩽7.35, PaCO2 is >
45 mmHg and the respiratory rate is > 20–24 breaths/mi-
nute despite standard medical therapy [105]. The authors
suggest that there is no lower limit of pH below which a
trial of NIV is inappropriate even if close monitoring is
needed in patients with a lower pH due to a greater risk of
failure due to the possibility of a rapid endotracheal intub-
ation [105]. Previous [106] and recent Cochrane reviews
[107] confirm the effectiveness of NIMV on very severe
outcome such as need for endotracheal intubation and
mortality, and the magnitude of advantages appears simi-
lar for patients with mild acidosis (pH 7.30 to 7.35) versus
severe (pH < 7.30), and when NIMV is applied in the ICU
or in a ward setting [107].
A cornerstone study about NIMV in hospitalized
AECOPD was conducted by Brochard and colleagues [99].
In a prospective, randomized study comparing NIMV plus
standard treatment (oxygen until a maximal flow rate of
5 L/m by nasal prongs, in order to achieve an arterial oxy-
gen saturation above 90%, antibiotics, bronchodilators,
and corticosteroids or/and aminophylline) versus standard
treatment in patients admitted to the ICU, the authors
demonstrated a reduction in the need for endotracheal in-
tubation (26% versus 74%, p < 0.001 in NIMV and stand-
ard therapy, respectively). Furthermore, the percentage of
complications not present on admission (such as
pneumonia, barotrauma, gastrointestinal hemorrhage,
renal insufficiency, neurologic events, and pulmonary
embolism) (16% versus 48%, p = 0.001), the mean
length of hospital stay (23 ± 17 days versus 35 ± 33,
p = 0.005), and the mortality rate (9.3% versus 28.5%,
p = 0.02) were lower in the NIMV group in compari-
son to standard treatment [99]. The same outcomes
have been demonstrated in other trials, including in
patients admitted to a general respiratory ward
[102, 108], or performed on patients with different
etiologies of ARF other than COPD (non-COPD-related
pulmonary process, neuromuscular disease, and status
post-extubation) [103]. Improvements in dyspnea sensation
after NIMV use have also been documented [109, 110].
Finally, the long-term survival of AECOPD patients was
better in those treated with NIMV [111].
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To evaluate the cost effectiveness of NIMV an incre-
mental cost analysis per in-hospital death of 236 patients
with mild to moderate respiratory acidosis (pH 7.25–
7.35) due to a severe AECOPD and admitted to 14 med-
ical wards in the United Kingdom was performed [112].
Patients receiving NIMV had a reduction in costs of
£49.362 (78.741 $; 73.109 €), mainly through reduced
use of ICU admission [112]. The incremental cost effect-
iveness ratio was -£645/death avoided (95% CI -£2310 to
£386), demonstrating that NIMV is a highly cost-effective
strategy [112].
Generally, NIMV requires the use of facial or nasal
interfacies that are key variables for the success of treat-
ment [113, 114]. However, a recent study demonstrated,
during an episode of acute hypercapnic respiratory fail-
ure, that a new helmet may be a valid alternative to a
mask in improving gas analysis, achieving a good toler-
ance [115]. Therefore, the sequential use of a mask and
helmet diminished the incidence of failure [116]. Finally,
an open mouthpiece method of ventilation, similar to
traditional NIV delivered by a nasal mask, has been
reported to be a useful technique, preventing further de-
terioration of gas exchange in AECOPD patients with
mild to moderate acidosis [117]. According to strategies
to improve the optimization of patient-ventilator interac-
tions, the analysis of flow and pressure waveforms gener-
ated by ventilators can be useful [118]; optimized
ventilation led to a more rapid normalization of pH at
2 h, to a significant improvement of the patient’s toler-
ance to ventilation at 2 h, and to a higher reduction in
PaCO2 at 2 and 6 h [118].
Among strategies to improve the efficacy of NIMV the
use of an inhaled helium/oxygen mixture (heliox) in-
stead of an air/oxygen mixture has been proposed as
adjunctive therapy to NIMV in severe AECOPD. The ra-
tionale for the use of helium is related to the low density
of this element in comparison to air. Physiologically, in
10 patients with AECOPD heliox reduced the work of
breathing and PCO2 levels without significantly chan-
ging their breathing pattern or oxygenation [119]. Al-
though a helium/oxygen mixture improves respiratory
acidosis and the respiratory rate more quickly than air/
O2 [120], some recent trials in hypercapnic AECOPD
patients found no significant effects of helium/oxygen
mixture on clinical outcomes, such as the rate of NIMV
failure [120–122] or intubation rate [123].
Regarding predictors of NIMV failure, the severity of
hypercapnia and acidosis at admission are associated
with the early failure of treatment [111, 124], while im-
provements in acidosis and respiratory rate after 4 h of
NIMV were associated with success. Charts of risk de-
scribe the probability of failure in ARF patients treated
with NIMV [125]. Very recently, the early and noninva-
sive ultrasound evaluation of diaphragmatic dysfunction
(DD) during severe AECOPD has been proved to be reli-
able and accurate in identifying patients at major risk for
NIMV failure and worse prognosis [126]. Patients with
DD, evaluated by a change in diaphragm thickness
(ΔTdi) < 20% during tidal volume, had a higher risk for
NIMV failure than patients without DD (risk ratio 4.4; p
< 0.001), and this was significantly associated with higher
in-hospital and 90-day mortality rates, longer mechanical
ventilation duration, higher tracheostomy rate, and longer
ICU stay [126]. The accuracy to predict failure by ΔTdi <
20% was higher than baseline pH value and early change
in both arterial blood pH and partial PCO2 following the
initiation of NIV (area under the curve [AUC] was 0.84,
0.51, 0.56, and 0.54, respectively; p < 0.0001) [126].
Main take home messages
NIMV represents the main treatment for hypercapnic
ARF patients with associated respiratory acidosis. Al-
though the HFNC oxygen therapy is able to reduce the
level of hypercapnia, the use in clinical practice appears
controversial and not clear due to very limited studies.
At the moment a cautious approach appears motivated.
Unmet needs or future clinical research
In AECOPD patients with moderate respiratory acidosis
(pH between 7.35 and 7.25) prospective randomized
noninferiority trials considering HFNC oxygen therapy
versus NIMV are ongoing [127, 128] with the aim to
evaluate physiological [128] or clinical (endotracheal in-
tubation prevention) [127] effects. Future studies need
to clarify when or not HFNC may be proposed as a valid
alternative choise for hypercapnic ARF patients and
when could be better to swich to NIMV; such as endo-
tracheal intubation for NIMV, a delay in treatment with
HFNC could have a worse outcome in AECOPD patient.
Pulmonary rehabilitation
Pulmonary rehabilitation (PR) is a comprehensive non-
pharmacological treatment to which COPD is most suscep-
tible to improvements [129]. Exercise capacity and symp-
toms such as dyspnea and quality of life represent the main
outcomes [129–132]. PR benefits COPD patients with
different functional stages [133] and different phenotypes
[134], the elderly [135], those with fewer or more comor-
bidities [136, 137], those with physical frailty [138], and
even cachectic patients [139]. Historically, PR has been pro-
posed for COPD patients in a stable phase of disease [129]
and just after an AECOPD exacerbation [140], but not dur-
ing AECOPD due to safety-related aspects. However, recent
evidence also demonstrates the efficacy of a PR program
for severe hospitalized AECOPD patients [141–147].
AECOPD reduces the physical activity of patients
[148]. Hospitalization due to AECOPD leads to physical
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and functional impairment [149] with loss of quadriceps
muscle strength [150], exercise tolerance [151] and
health status [152]. The role of PR during hospitalization
may thus be justified.
The first evidence on PR in respiratory acute patients
was published by Trooster and colleagues in 2010 [141]
and opened up new possibilities for early rehabilitation
treatment [153]. The authors demonstrated, in a ran-
domized trial on 40 severe AECOPD, that an additional
resistance training program is feasible and safe during
hospitalization and can prevent muscle deterioration
[141]. Patients who received training showed an im-
provement in quadriceps force and walking capacity
(documented by 6MWD [6-min walking distance]) at
discharge; improvements were also documented at
1 month of follow up [141]. Similar and very recent
studies on severe hospitalized AECOPD patients [142]
and frail-elderly patients [143] suggest improvements in
lower-limb muscle strength [142, 143], balance [143], ex-
ercise capacity [142, 143], and quality of life [142]. Feasi-
bility studies on neuromuscular electrical stimulation
(NMES) showed improvements in quadriceps muscle
strength [154, 155]. Thus, all studies proposed for severe
hospitalized AECOPD patients have found rehabilitative
intervention to be feasible and safe [142–146, 154, 155].
At this point in time, only one randomized trial [156]
aimed at reducing the readmission rate at 12 months
(outcome failed) has documented a higher mortality
risk in the treated group (OR 1.74, 95% CI 1.05 to
2.88, p = 0.03) [156]; however, the difference in mor-
tality began > 5 months after the completion of the
intervention and was not related to the early rehabili-
tation intervention [157].
Main take home messages
In hospitalized AECOPD an early PR program has proved
to be feasibility and safe. However, there are still few evi-
dences to recommend this treatment for patients admitted
to hospital.
Unmet needs or future clinical research
Prospective studies are needed to identify the PR inter-
ventions providing the greatest benefits.
Summary of recommendations or suggestions
Table 4 reports the summary of recommendations or
suggestions from the GOLD document, NICE guidelines
and ERS/ATS guidelines about the pharmacological and
non-pharmacological treatments used in the manage-
ment of a severe AECOPD.
Non-conventional drugs
Some non-conventional approaches have been proposed
in severe AECOPD [158–160].
In a randomized double-blinded clinical trial the effect
of nebulized furosemide (40 mg) as an adjunct to con-
ventional treatment has been tested in the emergency
department on 100 AECOPD patients [158]. Changes in
dyspnea perception, FEV1, arterial blood gas variables,
blood pressure, breathing frequency, and heart rate at
baseline and at 1 h were the study measurements. In
both groups (nebulized furosemide and saline) all mea-
sured variables were improved at 1 h, although FEV1,
dyspnea score, PaO2, pH, blood pressure, breathing fre-
quency, heart rate, improved significantly more in the
furosemide group. Patients presenting a lower FEV1 on
admission had more benefit from furosemide than those
who had a higher baseline FEV1 [158].
Another randomized, placebo-control, double-blind,
crossover trial [159] enrolling 24 AECOPD patients has
tested the effect of magnesium sulfate (1.5 g intravenous
for 20 min). FEV1 was measured after 15, 30, and
45 min of magnesium sulfate or placebo administration
and after a dose of 400 μg of salbutamol. In term of
FEV1 after 15, 30, and 45 min no differences were found
between groups, while the FEV1 measured after salbuta-
mol found significantly greater increases in the magne-
sium sulfate group in comparison to placebo (+ 0.185 L
and + 0.081 L; p = 0.004, respectively) [159]. In conclu-
sion, the magnesium sulfate has no bronchodilatation ef-
fect in AECOPD patients, although it enhances the
bronchodilating effect of salbutamol [159].
The last randomized double-blind, placebo-controlled,
parallel group trial has evaluated the effect of oral zileu-
ton (a 5-lipoxygenase inhibitor having an effect on leu-
kotrienes) at the dose of 2400 mg daily for 14 days
[160]. The primary outcome was the length of hospital
stay, while the secondary ones were treatment failure
and biomarkers of leukotriene production. There was no
difference in the length of hospital stay (3.75 days versus
3.86 days, p = 0.39 for zileuton and placebo groups, re-
spectively) and treatment failure (23% versus 27%, p =
0.63 for zileuton and placebo groups, respectively), des-
pite a decline in urinary leukotrienes levels in the
zileuton-treated group at 24 and 72 h [160]. Due to the
slow recruitment the study has been stopped before the
enrollement target and for this reason the sample size
analysed may have been insufficient for the meaningful.
Conclusion
Several treatments exist for severe AECOPD patients
requiring hospitalization. However, some treatments lack
strong evidence. Strong evidence currently exists for
steroids and NIMV, in patients admitted with a hyper-
capnic acute respiratory failure and respiratory acidosis.
HFNC oxygen therapy needs further evidences to be
suggested. Concerning the use of antibiotics, while many
benefits have been reported for ICU patients, there is a
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lack of evidence on the preferred drug and optimal dur-
ation of treatment for hospitalized patients. Early re-
habilitation, if associated with standard treatment of
patients, should be proposed due to its feasibility and
safety: we should apply the rule that “more is better’”.
There are currently few options involving new drugs or
new applications of existing drugs.
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Table 4 Summary of recommendations or suggestions from the GOLD document, NICE guidelines and ERS/ATS guidelines about
management of severe AECOPD
In-hospital AECOPD
treatments
GOLD document NICE guidelines ERS/ATS guidelines
Bronchodilators SABA with or without short-acting anticholinergics
are the initial bronchodilators recommended. It is
recommended that patients do not receive
continuous nebulization, but use the MDI inhaler.
It is recommended continuining long-acting
bronchodilators or starting as soon as possible
Increased doses of short-acting
bronchodilators are suggested.
Both nebulisers and
hand-held inhalers can be
used to administer inhaled
therapy. Patients should be
changed to hand-held
inhalers as soon as their
condition has stabilised
It is not reported
Steroids Prednisone 40 mg per day for 5 days is
recommended. Therapy with oral prednisolone
is equally effective to intravenous administration
Prednisolone 30 mg orally




low quality of evidence)
Antibiotics They should be given in patients who have: all three
symptoms (increase in dyspnea, sputum volume,
and sputum purulence); increased sputum purulence;
required mechanical ventilation. The recommended
length of therapy is 5 to 7 days
Antibiotics should be used to
treat exacerbations of COPD
associated with a history of
more purulent sputum
It is not reported for hospitalized
patients with AECOPD
Oxygen therapy If necessary, oxygen should be given to keep the
SaO2 within the individualised target range
Supplemental oxygen should
be titrated to improve
hypoxemia, with a target
SaO2 of 88 to 92%
It is not reported
HFNC In patients with hypoxemic ARF it may be an alternative
to standard oxygen therapy or NIMV. There is a need
for well-designed, randomized, multicenter trials to
study the effects of HFNC in hypoxemic/hypercapnic
ARF.
It is not reported It is not reported
NIMV It is indicated in patients with respiratory acidosis or
severe dyspnoea with clinical signs suggestive of
respiratory muscle fatigue, increased work of breathing,
or persistent hypoxemia despite supplemental oxygen
therapy
It should be used as the





It is recommended for patients






It is not reported for hospitalized patients with AECOPD It is not reported for
hospitalized patients with
AECOPD
It is suggested not initiating
during hospitalisation (conditional
recommendation, very low quality
of evidence)
Reported from references [1, 9, 10]
Abbreviations: SABA indicates short-acting β2 agonists, MDI metered-dose inhaler, HFNC high flow nasal cannulae oxygen therapy, NIMV non-invasive mechanical
ventilation, SaO2 oxygen saturation, ARF acute respiratory failure
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